AKT1 and prostate cancer: In a related context, miR‐143‐3p was shown to inhibit EMT in prostate cancer by targeting AKT1 [34] and to curb bone metastasis of Gleason 3+4 prostate cancer by targeting the LASP1‐mediated Wnt pathway [35].